Sister Mary Joseph's Nodule as a First Manifestation of Primary Peritoneal Cancer
Sent from my iPhone
Monday, November 12, 2012
Antiangiogenic agents as a maintenance - PubMed Mobile
Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
Bevacizumab is the first antiangiogenic agent to have demonstrated benefit as first-line and maintenance therapy in epithelial ovarian cancer (EOC), with the Gynecologic Oncology Group 218 and ICON 7 phase III trials revealing significantly prolonged progression-free survival (PFS) for carboplatin/paclitaxel plus bevacizumab followed by bevacizumab maintenance versus carboplatin/paclitaxel alone. Results are forthcoming from several phase III maintenance trials of investigational antiangiogenic agents, each evaluating PFS as the primary endpoint: AGO-OVAR12/LUME-Ovar1 (nintedanib [BIBF 1120]), AGO-OVAR16 (pazopanib), and TRINOVA-1, -2, and -3 (AMG 386). Here we review available data and ongoing clinical trials of investigational antiangiogenic agents as maintenance therapy for EOC. Current controversies, including uncertainties regarding the (1) most appropriate clinical trial endpoints, (2) optimal dosing, duration, and timing of therapy (e.g., with first-line chemotherapy and/or as maintenance monotherapy), and (3) feasibility, tolerability, and cost of adding these agents to platinum/taxane regimens are also highlighted.
Ovarian Cancer, Version 3.2012. - PubMed Mobile
These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.
http://www.nccn.com
http://www.ncbi.nlm.nih.gov/m/pubmed/23138163/?i=5&from=ovarian%20cancer
Sent from my iPhone
Sunday, November 11, 2012
Ovarian cancer patients have lower mortality rates when treated at high-volume hospitals | Science Codex
Ovarian cancer patients have lower mortality rates when treated at high-volume hospitals | Science Codex
New York, NY (Nov. 8, 2012) – A study by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/Columbia University Medical Center, recently e-published ahead of print by the Journal of Clinical Oncology, suggests that women who have surgery for ovarian cancer at high-volume hospitals have superior outcomes than similar patients at low-volume hospitals.
The improved survival rate is not dependent on a lower rate of complications following surgery, but on the treatment of the complications. In fact, patients with a complication after surgery at a low-volume hospital are nearly 50 percent more likely to die as a result of the complication than patients seen at high-volume hospitals.
"It is widely documented that surgical volume has an important effect on outcomes following surgery," said lead author Jason D. Wright, MD, the Levine Family Assistant Professor of Women's Health and the Florence Irving Assistant Professor of Obstetrics and Gynecology at CUMC, a gynecologic oncologist at NYP/Columbia, and a member of the HICCC.
"We examined three specific areas: the influence of hospital volume on complications, failure to rescue from......
Saturday, November 10, 2012
Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
ScienceDirect.com - Gynecologic Oncology - Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
Highlights
►
Visual estimation of tumor spread in advanced epithelial ovarian cancer
is impaired by the use of neoadjuvant chemotherapy
► This may lead to leaving microscopic residual tumor in the patient in interval debulking surgery
► This hypothesis should be tested in prospective studies specifically designed to address this issue
► This may lead to leaving microscopic residual tumor in the patient in interval debulking surgery
► This hypothesis should be tested in prospective studies specifically designed to address this issue
Urology Care Foundation - Urology A-Z - Cancer of the Ureter and Renal Pelvis
Urology Care Foundation - Urology A-Z - Cancer of the Ureter and Renal Pelvis
What is upper urinary tract cancer?
It is a disease in which cancer cells are found in the tissues lining the collection reservoir (urothelial cells) of the kidneys - the renal pelvis - and/or in the ureters that connect the kidneys to the bladder.
Friday, November 09, 2012
Cancers | Free Full-Text | Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
Blogger's Note: long and technical paper; value to patients: list of specific mutations
Cancers | Free Full-Text | Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
Clinicopathologic features of brain metastases from gynecologic malignancies: A retrospective study of 139 cases (KCOG-G1001s trial)
Clinicopathologic features of brain metastases from gynecologic malignancies: A retrospective study of 139 cases (KCOG-G1001s trial)
Highlights
►
Brain metastases from ovarian/tubal/peritoneal cancer revealed better
prognosis compared to those from corpus cancer or cervical cancer.
► Ovarian/tubal/peritoneal origin, KPS > 70, single metastasis, absence of extracranial disease, cranial surgery, radiotherapy, and chemotherapy are independent favorable prognostic factors.
► Aggressive multimodal therapy is warranted in the treatment of brain metastases from gynecologic malignancies in carefully selected patients.
► Ovarian/tubal/peritoneal origin, KPS > 70, single metastasis, absence of extracranial disease, cranial surgery, radiotherapy, and chemotherapy are independent favorable prognostic factors.
► Aggressive multimodal therapy is warranted in the treatment of brain metastases from gynecologic malignancies in carefully selected patients.
repost: Upper urinary tract carcinoma in Lynch syndrome cases. [J Urol. 2011] - PubMed - NCBI (note: cancer of the ureter)
Upper urinary tract carcinoma in Lynch syndrome cases. [J Urol. 2011] - PubMed - NCBI
Source
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA. david.crockett@unmc.eduAbstract
PURPOSE:
Patients with Lynch syndrome are much more likely to have generally rare upper urinary tract urothelial carcinoma but not bladder urothelial carcinoma. While the risk has been quantified, to our knowledge there is no description of how this population of patients with Lynch syndrome and upper urinary tract cancer differs from the general population with upper urinary tract cancer.RESULTS:
Of the patients with Lynch syndrome 91% had mutations in MSH2 rather than in MSH1 and 79% showed upper tract urothelial carcinoma a mean of 15.85 years after prior Lynch syndrome-type cancer. Median age at diagnosis was 62 years vs 70 in the general population (p <0.0001). Only half of our patients had a significant smoking history and the male-to-female ratio was 0.95. Of patients with Lynch syndrome 51% had urothelial carcinoma in the ureter while it occurred in the renal pelvis in 65% of the general population (p = 0.0013). Similar numbers of high grade tumors were found in the Lynch syndrome and general populations (88% and 74%, respectively, p = 0.1108).3 presentations: Beyond Antiangiogenesis: Contemporary Strategies in Relapsed Ovarian Cancer
Beyond Antiangiogenesis: Contemporary Strategies in Relapsed Ovarian Cancer
Relapsed ovarian cancer: Defining the drivers of the disease
Nicoletta Colombo, MD
Bradley Monk, MD, FACS, FACOG
open access: Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer (Coukos et al)
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
Abstract:
Novel strategies for the therapy of recurrent ovarian cancer are
warranted. We report a study of a combinatorial approach encompassing
dendritic cell (DC)-based autologous whole tumor vaccination and
anti-angiogenesis therapy, followed by the adoptive transfer of
autologous vaccine-primed CD3/CD28-co-stimulate
d lymphocytes. Recurrent
ovarian cancer patients for whom tumor lysate was available from prior
cytoreductive surgery underwent conditioning with intravenous
bevacizumab and oral metronomic cyclophosphamide, sequentially followed
by (1) bevacizumab plus vaccination with DCs pulsed with autologous
tumor cell lysate supernatants, (2) lymphodepletion and (3) transfer of 5
× 109 autologous vaccine-primed T-cells in combination with
the vaccine. Feasibility, safety as well as immunological and clinical
efficacy were evaluated. Six subjects received this vaccination......
paywalled: PROGRESS IN OVARIAN CANCER TREATMENT THROUGH GCIG COLLABORATIVE TRIALSCANCER RESEARCH AND CLINICAL ONCOLOGY FOR THE NEXT DECADE
ILPROGRESS IN OVARIAN CANCER TREATMENT THROUGH GCIG COLLABORATIVE TRIALSCANCER RESEARCH AND CLINICAL ONCOLOGY FOR THE NEXT DECADE
Abstract
"Ovarian cancer is a relatively uncommon
tumour and progress in treatment has occured through small increments
requiring large-scale
trials. The Gynecological Cancer InterGroup was
formed in 1994 to encourage collaboration and avoid unnecessary
repetition
of research. Trials conducted by the
International Collaborative for Ovarian Neoplasia (ICON) Group and the
EORTC, Canadian
and Australian groups were the catalysts to
bring together a more formal collaboration of established national
trials groups.
The aims of the GCIG are to promote
international cooperation in clinical research, perform studies in rare
tumours, stimulate
evidence-based medicine and support educational
activities. Over the years, the GCIG has conducted many different
trials,
including GOG182-ICON5, the largest and fastest
recruiting trial in ovarian cancer, held four international consensus
conferences
on ovarian cancer to review evidence and set
standards, and developed strategies for research. A section of the GCIG
is directed
towards the facilitation of academic research
through harmonization of methodologies and developing common approaches
to lessen
the bureaucracy of clinical trial regulations.
The success of the GCIG results from
its relationship between participants, based on mutual respect, equality
and recognition
of the intellectual contribution from individual
group members. Landmark trials that have pushed forward our knowledge
will
be presented; however, the recognition that
ovarian cancer is not a single disease but one with an heterogenous
biology underlines
the need for a concerted international approach
to trials in what are effectively rare tumours. Maintenance of
intellectual
independence from industry is a major challenge
as the costs rise through ever increasing complex trial regulations.
However,
the current 23 Groups from Europe, North and
Central America, Far East and Australia represent a powerful body to
influence
industry and help direct future research."
Powerful Women, Powerful Choices | Free Health Care Symposium (Dr James Orr....)
Powerful Women, Powerful Choices | Free Health Care Symposium
James Orr, MD;
OVARIAN CANCER: Blood Test, Scans, Example & What else:
OVARIAN CANCER: Blood Test, Scans, Example & What else:
Lea Blackwell, MD;
BREAST CANCER: The Time and Place for Conservative Surgical Treatment
BREAST CANCER: The Time and Place for Conservative Surgical Treatment
Valerie Dyke, MD;
COLON CANCER: Early Detection Matters!
COLON CANCER: Early Detection Matters!
Thursday, November 08, 2012
open access: Paraneoplastic cerebellar degeneration associated with ovarian cancer
Paraneoplastic cerebellar degeneration associated with ovarian cancer
Published online on: Wednesday, November 7, 2012 |
Doi: 10.3892/ol.2012.1016 |
Abstract:
Paraneoplastic
cerebellar degeneration (PCD) is a rare neurological disorder
characterized by a widespread loss of Purkinje cells associated with a
progressive pancerebellar dysfunction. PCD often precedes the cancer
diagnosis by months to years. Here, we report the case of a 64‑year‑old
woman who developed PCD symptoms, associated with high levels of anti‑Yo
antibodies, one year after a previous diagnosis of ovarian cancer.
Clinical features, pathogenesis and treatment of PCD associated with
cancer are discussed according to previous studies.
|
Subscribe to:
Posts
(
Atom
)
